Онкология EXPERIENCE OF USING CABAZITAXEL (JEVTANA®) FOR THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CACNER AS SECOND-LINE CHEMOTHERAPY AFTER DOCETAXEL
eng
ONCOLOGY BULLETIN OF THE VOLGA REGION

Scientific-practical Journal for general practitioners and researchers

Search

EXPERIENCE OF USING CABAZITAXEL (JEVTANA®) FOR THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CACNER AS SECOND-LINE CHEMOTHERAPY AFTER DOCETAXEL

I.A. Koroleva, E.M. Lipaeva, M.V. Kopp, N.M. Konovalova

Samara Regional Clinical Oncology Dispensary

 

Abstract. The fi rst real-life experience with cabazitaxel for the treatment of metastatic castration-resistant prostate cancer has been described. Cabazitaxel was used as second-line treatment following disease progression on docetaxel treatment. Cabazitaxel was administered to two patients, with stable disease being registered in both the patients. Toxicity was mild, maximum grade 2, neutropenia and asthenia were registered. In general, Cabazitaxel had a manageable safety profi le.

Key words: castration-resistant prostate cancer, chemotherapy, Docetaxel, Cabazitaxel.





Наши партнеры



Copyright © 2014 | Все права защищены
RAFANDOS.COM | SUPPORT